1. Manganese-Doped Silica-Based Nanoparticles Promote the Efficacy of Antigen-Specific Immunotherapy.
- Author
-
Chandra J, Teoh SM, Kuo P, Tolley L, Bashaw AA, Tuong ZK, Liu Y, Chen Z, Wells JW, Yu C, Frazer IH, and Yu M
- Subjects
- Adjuvants, Immunologic pharmacology, Animals, CD8-Positive T-Lymphocytes immunology, Cancer Vaccines immunology, Cells, Cultured, Female, Humans, Immunization methods, Immunotherapy methods, Mice, Mice, Inbred C57BL, Mice, Transgenic, Papillomaviridae immunology, Papillomavirus E7 Proteins immunology, Papillomavirus Infections immunology, Papillomavirus Vaccines immunology, Polymorphism, Single Nucleotide immunology, Reactive Oxygen Species immunology, Signal Transduction immunology, Antigens, Neoplasm immunology, Manganese immunology, Nanoparticles administration & dosage, Neoplasms immunology, Neoplasms therapy, Silicon Dioxide immunology
- Abstract
Prophylactic human papillomavirus (HPV) vaccines are commercially available for prevention of infection with cancerogenic HPV genotypes but are not able to combat pre-existing HPV-associated disease. In this study, we designed a nanomaterial-based therapeutic HPV vaccine, comprising manganese (Mn
4+ )-doped silica nanoparticles (Mn4+ -SNPs) and the viral neoantigen peptide GF001 derived from the HPV16 E7 oncoprotein. We show in mice that Mn4+ -SNPs act as self-adjuvants by activating the inflammatory signaling pathway via generation of reactive oxygen species, resulting in immune cell recruitment to the immunization site and dendritic cell maturation. Mn4+ -SNPs further serve as Ag carriers by facilitating endo/lysosomal escape via depletion of protons in acidic endocytic compartments and subsequent Ag delivery to the cytosol for cross-presentation. The Mn4+ -SNPs+GF001 nanovaccine induced strong E7-specific CD8+ T cell responses, leading to remission of established murine HPV16 E7-expressing solid TC-1 tumors and E7-expressing transgenic skin grafts. This vaccine construct offers a simple and general strategy for therapeutic HPV and potentially other cancer vaccines., (Copyright © 2021 by The American Association of Immunologists, Inc.)- Published
- 2021
- Full Text
- View/download PDF